[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Portsmouth Hospitals NHS Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":311},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,38,60,82,102,127,155,187,209,228,249,272,292],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":34,"locationsCount":37},"100490046","novel-technologies-for-respiratory-virus-identification-100490046",false,"NCT05661032","Novel Technologies for Respiratory Virus Identification","ResVir Novel Technologies for Respiratory Virus Identification","ResVir","Inclusion Criteria:\n\n* Provide informed, (parental\u002Fguardian, where appropriate) consent\n* Able to provide nasopharyngeal swab\u002Faspirate specimens.\n* A clinical suspicion of a respiratory viral infection with one or more of the following symptoms:\n* Coryzal symptoms (runny nose, sneezing and\u002For nasal congestion)\n* New onset of cough\n* Sore throat\n* Head and\u002For Muscle aches\n* Fever or chills\n\nExclusion Criteria:\n\n* Unable to comply with study procedures or where in the opinion of the investigator, undertaking a nasopharyngeal swab may be detrimental to the individual\n* Lacking capacity to consent","ALL",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","Current virus detection methods often take significant time or can be limited in sensitivity, specificity or cost. There is therefore a need for diagnostic methods that are simple to use, sensitive, rapid and inexpensive.\n\nThis is a proof of concept study to determine whether the Pictura Bio system (a new a rapid pathogen identification technology) is able to detect and differentiate different viruses from nasopharyngeal swabs\u002Faspirate specimens. The data collected will be used to \"train\" the algorithms to be able to accurately identify respiratory viruses. The accuracy with which the algorithms estimate the test dataset will be monitored at regular intervals during the training dataset collection period. The Pictura Bio system is still under development, which means that it is still \"learning\". The system needs to see more information so that it can be sufficiently accurate to be used in clinical practice and should become more accurate in identifying these viruses as it sees more and more information from patients.\n\nThis study will take place at Portsmouth Hospitals University NHS Trust and aims to recruit 1000 patients. To do this, we will recruit both adults and children who either present to the emergency department or are admitted to QAH with a clinical suspicion of a respiratory viral infection. All participants will have a nose and\u002For throat swab taken as part of their clinical assessment, and we would ask to take a further nasal swab for the purpose of the study. Research sampling will be combined with routine clinical samples where possible to reduce the frequency of testing. We will use most of the information to teach the system how to become more accurate at identifying respiratory viruses. We will keep the remaining information separate and use it to test how accurate the system is. All of the data will be kept securely. Basic information will be collected including age, gender, results of blood tests taken for clinical review, treatment and outcome data. No results from the swabs taken for the purpose of the study will be available to either the participant or the clinical team and the information will have no effect on patient care.",[24,25],"Infections, Respiratory","Respiratory Tract Infections","RECRUITING","2026-06-26",{"date":29,"type":30},"2026-06-30","ACTUAL",{"date":32,"type":30},"2023-01-18",{"date":29,"type":20},{"name":35,"class":36},"Portsmouth Hospitals NHS Trust","OTHER_GOV",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":37},"100437961","portsmouth-core-d-routine-care-data-repository-100437961","NCT04983082","Portsmouth CORE-D Routine Care Data Repository","Portsmouth Clinical Outcomes REsearch Database (CORE-D)- a Research Database of Routine Electronically Recorded Patient Data to Model Adverse Clinical Outcomes and Healthcare Resource Usage","CORE-D","Inclusion Criteria:\n\n* Adult presenting at the acute hospital or receiving services from the hospital\n\nExclusion Criteria:\n\n* Adults who have registered an opt out of research with National Health Service (NHS) Digital\n* Adults who have contacted the hospital to ask that their records are not to be included in this study","16 Years",{"count":48,"type":20},750000,"An integrated database of depersonalised routine hospital patient data consisting of demographic and disease attributes, physiological or laboratory measurements, care contacts and interventions along with associated clinical outcomes. The database is an essential resource for the development and testing of risk models and classification systems, modified as necessary for patient subgroups, which can then be introduced into clinical care to improve patient outcomes. It can also be used for large scale simulations to evaluate interventions.",[51],"Adult Hospital Patients at Risk of Adverse Outcomes","2026-06-24",{"date":54,"type":30},"2026-06-29",{"date":56,"type":30},"2021-08-19",{"date":58,"type":20},"2031-04",{"name":35,"class":36},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":71,"studyType":21,"phases":4,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":37},"100288789","endoscopic-submucosal-dissection-for-early-gi-neoplasia-in-the-united-kingdom-100288789","NCT03039309","Endoscopic Submucosal Dissection for Early GI Neoplasia in the United Kingdom","Endoscopic Submucosal Dissection in the Treatment of Early Gastrointestinal Neoplasia: A UK Cohort Study to Assess Effectiveness and Safety","ESDUK","Inclusion Criteria:\n\n* Male or Female, aged 18 years or above undergoing endoscopic submucosal dissection\n* Participant is able to give informed consent for participation in the study\n\nExclusion Criteria:\n\n* Patients under the age of 18\n* Patients unable to give informed consent","18 Years",{"count":70,"type":20},500,"2 Years","Multicentre cohort study on the use of endoscopic submucosal dissection for the treatment of early gastrointestinal neoplasia.",[74],"Endoscopic Submucosal Dissection",[74],{"date":54,"type":30},{"date":78,"type":30},"2016-08-05",{"date":80,"type":20},"2028-08-04",{"name":35,"class":36},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100640663","include-ckd-inclusive-digital-care-for-chronic-kidney-disease-100640663","NCT07613593","INCLUDE-CKD: INCLUsive Digital carE for Chronic Kidney Disease","INCLUDE-CKD","Inclusion Criteria:\n\n5.1.1 Inclusion criteria - MyRenalCare users (retrospective and prospective cohorts)\n\nAdults will be eligible for inclusion in the MyRenalCare cohorts if they meet all of the following:\n\n1. Aged 18 years or over.\n2. Under the care of the Wessex Kidney Centre\n3. Registered with, or offered and subsequently enrolled onto, the MyRenalCare platform during the defined retrospective or prospective periods.\n4. Able to understand study information and, where applicable, provide informed consent for use of their data for research purposes.\n\nSpecific CKD stage definitions and thresholds (e.g. based on eGFR, albuminuria or uPCR) will be documented in the study manual to ensure consistent application.\n\n5.1.2 Inclusion criteria - matched usual care controls\n\nAdults will be eligible for inclusion in the matched control cohorts if they meet all of the following:\n\n1. Aged 18 years or over.\n2. Under the care of the Wessex Kidney Centre for chronic kidney disease.\n3. Not registered with or using MyRenalCare at any point during the relevant observation period.\n4. Have sufficient clinical and administrative data available in the renal electronic patient record to enable matching and outcome assessment.\n\nControls will be identified retrospectively from the renal electronic patient record and matched to MyRenalCare users using a predefined matching strategy.\n\n5.1.3 Inclusion criteria - qualitative interview participants (patients and staff)\n\nPatients will be eligible to take part in the qualitative interview component if they meet all of the following:\n\n1. Aged 18 years or over.\n2. Currently using, or recently offered, the MyRenalCare platform as part of their CKD care at the Wessex Kidney Centre.\n3. Able to understand spoken and written English to the extent required for participation in an interview.\n4. Able and willing to provide written informed consent for participation in a recorded interview.\n5. Belong to a demographic or clinical subgroup of interest for the study (e.g. varying age, ethnicity, CKD stage, or digital engagement level), as part of purposive sampling to support diversity and equity analysis.\n\nClinical staff will be eligible if they meet all of the following:\n\n1. Employed by PHU or working in direct partnership with the Wessex Kidney Centre.\n2. Directly involved in the care of patients with chronic kidney disease and\u002For in the implementation or support of MyRenalCare.\n3. Able and willing to provide informed consent for a recorded interview.\n4. Able to reflect on experiences and observations relevant to the delivery, uptake, or equity implications of digital health in CKD.\n\nExclusion Criteria:\n\n1. Patients with acute kidney injury without established chronic kidney disease.\n2. Patients with a very limited life expectancy where participation in routine digital monitoring is not appropriate, as judged by the clinical team.\n3. Patients who have previously indicated that they do not wish their routinely collected clinical data to be used for research where such opt-out applies to this study.\n4. Patients who are unable to be identified reliably in the available data sources (for example, inconsistent or missing key identifiers).\n5. Any other situation where, in the opinion of the responsible clinician, participation in the study processes (including data use) would be inappropriate or unduly burdensome.\n6. Clinical staff who are not directly involved in the care of patients with chronic kidney disease or in the implementation of the MyRenalCare platform.\n7. Staff members currently on extended leave or unable to participate during the data collection period.\n8. Individuals who do not wish to have their views included in recorded interview transcripts or are unable to provide informed consent for participation.\n9. Any situation where, in the opinion of the study team or the individual's manager, participation would be inappropriate or burdensome due to role, availability, or conflict of interest.",{"count":19,"type":20},"This study will provide valuable insights into the demographics of MyRenalCare users, their digital adherence, and the overall impact of the app on health outcomes, healthcare costs, and environmental sustainability.",[92],"Chronic Kidney Disease","NOT_YET_RECRUITING","2026-05-21",{"date":96,"type":30},"2026-05-29",{"date":98,"type":20},"2026-05-19",{"date":100,"type":20},"2026-12-31",{"name":35,"class":36},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":37},"100625752","a-study-measuring-markers-of-airway-inflammation-in-breath-samples-from-people-with-respiratory-diseases-and-healthy-volunteers-100625752","NCT07426718","A Study Measuring Markers of Airway Inflammation in Breath Samples From People With Respiratory Diseases and Healthy Volunteers.","An Expanded inVestigation of Inflammacheck™ to Measure Exhaled Breath CondensaTe Hydrogen perOxide in RespiratorY Conditions A Cross-sectional, Observational Study Comparing Exhaled Breath Biomarkers Across Respiratory Diseases and Healthy Volunteers.","VICTORY 2","Inclusion Criteria:\n\n\\- 1. Age: Adults aged ≥18 years. 2. Consent: Willing and able to provide written informed consent (prospective participants only).\n\n3\\. Clinical status: Belong to one of the defined diagnostic categories listed below:\n\n1. Group A: Lung cancer confirmed by multidisciplinary team (MDT) diagnosis.\n2. Group B: Suspected lung cancer (biopsy negative or awaiting further investigation).\n3. Group C: Pneumonia (radiologically or clinically confirmed).\n4. Group D: Non-malignant airways diseases (asthma or COPD).\n5. Group E: Other non-malignant respiratory diseases (interstitial lung disease, bronchiectasis, breathing pattern disorder).\n6. Group F: Healthy controls with no known respiratory disease. 4. Clinical documentation: Availability of relevant diagnostic and demographic data to confirm disease classification (for retrospective participants).\n\n   5\\. Previous participation: Individuals previously enrolled in the VICTORY or ExPeL studies may be included for retrospective data integration.\n\n   6\\. Willing and able to perform a breath test using the Inflammacheck® device. 7. Willing to allow access to relevant clinical data and imaging results 8. Be able to understand and communicate in English with or without the need for a translator, to ensure informed consent and comprehension of study procedures\n\n   Exclusion Criteria:\n   * 1\\. Active respiratory infection (e.g., tuberculosis, bronchopneumonia) other than pneumonia (e.g., tuberculosis) at the time of breath sampling.\n\n     2\\. History of major thoracic surgery or lung resection within the previous six months.\n\n     3\\. Current or recent chemotherapy or radiotherapy for lung cancer at the time of breath sampling (except for retrospective confirmed cancer cases where data were collected pre-treatment).\n\n     4\\. Severe cognitive impairment, communication barriers, or any condition preventing informed consent or compliance with study procedures.\n\n     5\\. Pregnancy or breastfeeding. 6. Active use of cannabis or recreational drugs known to alter exhaled breath composition.\n\n     7\\. Current active tobacco smoking within the past 12 hours prior to breath collection will be an exclusion criterion, as will the use of vaping or e-cigarettes within this period, to prevent contamination of exhaled breath samples 8. Participants who have taken systemic antibiotics or commenced a new course of oral or inhaled corticosteroids within the preceding two weeks will also be excluded, as these may transiently alter inflammatory biomarkers in exhaled breath (this is not applicable to participants with pneumonia). Stable use of maintenance inhaled corticosteroids in patients with chronic respiratory conditions (e.g., asthma, COPD) will be permitted, provided dosing has remained unchanged for at least four weeks prior to sampling.\n\n     9\\. Any condition that, in the opinion of the investigator, could compromise participant safety or the integrity of the data.\n\n     10\\. Unable or unwilling to provide informed consent. 11. Unable to complete the breath test due to physical or cognitive limitations.\n\n     12\\. Currently participating in another interventional clinical trial that may confound breath biomarker data.\n\n     13\\. Received systemic treatment for lung cancer prior to breath sampling (for the lung cancer group only).\n\n     14\\. History of any active cancer within the past 12 months (excluding basal cell carcinoma of the skin or cervical carcinoma in situ), except for those in the confirmed lung cancer group.\n\n     15\\. They have any active respiratory infection other than pneumonia (e.g., tuberculosis) at the time of breath sampling.\n\n     16\\. They have undergone a bronchoscopy or invasive respiratory procedure within the past 48 hours, due to the potential for artefacts in breath data.\n\n     17\\. Pneumonia with concurrent lung cancer, thoracic malignancy or lung fibrosis. Pneumonia with co-existent asthma or COPD can be included at discretion of the PI.",true,{"count":112,"type":20},140,"Lung cancer remains the leading cause of cancer-related death in the UK, with over 35,000 deaths annually and most cases diagnosed at a late stage. Current screening programmes using low-dose CT scans target only high-risk individuals, missing around 30% of lung cancer cases, including many women and never-smokers. There is no simple, non-invasive tool to help triage patients with persistent respiratory symptoms who fall outside formal screening criteria. Inflammacheck® measures hydrogen peroxide and other breath biomarkers linked to airway inflammation and oxidative stress. Preliminary studies (VICTORY and ExPeL) have shown strong diagnostic performance for distinguishing lung cancer from other respiratory conditions. VICTORY 2 aims to validate and refine the AI model supporting Inflammacheck®, enabling accurate, rapid, and affordable triage for suspected lung cancer in NHS settings.",[115,116,117,118],"Lung Cancer (Diagnosis)","Lung Cancer (Suspected or Confirmed)","Healthy","Pneumonia","2026-05-05",{"date":121,"type":30},"2026-05-08",{"date":123,"type":30},"2026-03-05",{"date":125,"type":20},"2026-12-30",{"name":35,"class":36},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":110,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":37},"100601544","healthcare-services-for-older-people-who-have-fallen-with-potential-head-injury-100601544","NCT07111871","Healthcare Services for Older People Who Have Fallen With Potential Head Injury","Understanding Care Pathways for Older People on Anticoagulant or Antiplatelet Medications With Falls and Head Injury","Anti-HI-Falls","Inclusion Criteria:\n\n* • Aged 18 years or above\n\n  * Healthcare professional whose primary employment is within HIOW\n  * Have experience reviewing older adults on anticoagulant or antiplatelet medications who have had a fall as part of their job role\n  * Confirmed consent to participate on the completed survey\n\nExclusion Criteria:\n\n* • Did not consent to participate on the completed survey",{"count":19,"type":20},"Every year, one in three older people (\\>65 years old) experience a fall. Older people may have long-term health conditions and take medications that can increase their risk of bleeding (blood thinners). The UK national guidelines recommend that older people who are on blood thinning medications should have a CT head scan considered due to concerns of a brain bleed if they have hit their head after a fall. Many older people are therefore brought into hospital for assessment. However, the risk of bleeding in the brain is very low especially if older people do not have any symptoms such as loss of consciousness, weakness, headaches or vomiting. Some people could experience long waits in the emergency department or end up being admitted to hospital unnecessarily. This could worsen mobility, cause confusion, pressure sores or infections in older people.\n\nMore importantly, older people should have a comprehensive falls assessment to reduce their risk of future falls and have their medications reviewed after experiencing a fall. These assessments could potentially take place in their own homes if they prefer, rather than in hospital. Yet, current healthcare services outside the hospital setting may not be set up to manage an older person after fall.\n\nUsing an online survey, the investigators want to understand how current healthcare services in the Hampshire and Isle of Wight (HIOW) region work to look after older people who have had a fall. The study will focus particularly on older people taking blood thinning medications who may have a head injury but do not have any symptoms. The investigators will ask NHS workers what their role is, where they work and what they do when assessing an older person who has fallen if there is a concern about head injury. The survey will also ask participants to describe what challenges they may face, and if they have any suggestions to improve the care for older people.\n\nThis study will help the investigators understand what services are available in our current healthcare system for older people on blood thinning medications who have fallen and may have a head injury. The investigators hope that the results will help improve how healthcare services can work together with older people and their closed ones to provide care based on what matters most to them in their preferred place of care. This could reduce unnecessary use of emergency services and hospital admissions for older people.",[138,139,140],"Older Adults (65 Years and Older)","Falls","Head Injury",[142,143,144,139,145,146],"Older People","Anticoagulants","Antiplatelets","Head injury","Care pathways","2025-12-16",{"date":149,"type":30},"2025-12-23",{"date":151,"type":30},"2025-09-11",{"date":153,"type":20},"2026-05-31",{"name":35,"class":36},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":165,"phases":166,"briefSummary":168,"conditions":169,"keywords":175,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":37},"100602107","surgical-techniques-robotic-versus-conventional-laparoscopic-cholecystectomy-in-benign-gallbladder-disease-100602107","NCT07119203","Surgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease","Surgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease: A Randomized Controlled, Open, Parallel, Non-inferiority, Single-center Trial (STaRLING Trial)","STaRLING","Inclusion Criteria:\n\n* Age equal or above 18 years;\n* Benign gallbladder disease: diagnosis of gallbladder polyps or symptomatic gallstones proven on imaging (ultrasound, computed tomography (CT) scan or magnetic resonance cholangiopancreatography (MRCP));\n* Capacity to give informed consent.\n\nExclusion Criteria:\n\n* Minimally invasive procedure is not deemed possible by the operating surgeon;\n* Evidence of acute cholecystitis;\n* Known stones in the common bile duct (CBD);\n* Suspicion of possible malignancy;\n* Pregnancy;\n* Diagnosis of liver cirrhosis (stage III or IV);\n* Insufficient language skills to be able to perform the quality-of-life questionnaires.",{"count":164,"type":20},276,"INTERVENTIONAL",[167],"NA","This is a single-center, randomized controlled, parallel, non-inferiority trial. All adult patients with benign gallbladder disease with an indication for cholecystectomy will be assessed for eligibility and included after obtaining informed consent. A total of 276 patients will be randomized to undergo either robotic cholecystectomy (RC) or laparoscopic cholecystectomy (LC). The primary endpoint will be the incidence and severity of postoperative complications within 30 days after surgery. Secondary endpoints include perioperative outcomes, total health care utilization, health-related quality of life (HR-QoL) as assessed by patient-reported outcome measures, and cost-effectiveness. Follow-up assessments will be conducted at 7 and 30 days postoperatively.\n\nThis is the first randomized controlled trial designed to compare RC with LC in the treatment of benign gallbladder disease. The trial aims to evaluate the safety and non-inferiority of RC relative to LC, providing important evidence to guide the progress and adoption of robotic surgery in clinical practice.",[170,171,172,173,174],"Cholecystectomy, Robotic","Cholecystectomy, Laparoscopic","Cholecystectomy","Gallstones","Benign Gallbladder Disease",[176,177,178,179,180],"Robotic cholecystectomy","Laparoscopic cholecystectomy","Benign gallbladder disease","Randomized controlled trial","Cost-effectiveness",{"date":149,"type":30},{"date":183,"type":30},"2025-09-12",{"date":185,"type":20},"2026-06-01",{"name":35,"class":36},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":110,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":37},"100434477","evaluation-of-neoplasia-with-artificial-intelligence-in-gastrointestinal-endoscopy-100434477","NCT04937647","Evaluation of Neoplasia With Artificial Intelligence in Gastrointestinal Endoscopy","Collection of Endoscopic Images and Videos for Validation of Artificial Intelligence Algorithms for Computer Aided Detection and Characterisation of Early Gastrointestinal Neoplasia","NEW-AGE","Inclusion Criteria:\n\n-The participant must meet ALL of the following criteria to be considered eligible for the study:\n\n* Male or Female, aged 18 years or above.\n* Requiring gastroscopy and\u002For colonoscopy to investigate gastrointestinal symptoms, or as part of screening or ongoing surveillance of GI neoplasia.\n* Participant is willing and able to give informed consent for participation in the study.\n\nExclusion Criteria\n\nThe participant may not enter the study if ANY of the following apply:\n\n* Patients with endoscopically active severe oesophagitis\n* Poor bowel preparation",{"count":196,"type":20},1650,"This study aims to validate and evaluate AI algorithms for detection and characterization of early GI neoplasia.",[199],"Gastrointestinal Neoplasms",[201,202],"gastrointestinal neoplasia","artificial intelligence",{"date":149,"type":30},{"date":205,"type":30},"2021-06-16",{"date":207,"type":20},"2026-06-03",{"name":35,"class":36},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":110,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":216,"targetDuration":217,"studyType":21,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":227},"100412030","polycystic-liver-disease-registry-uk-100412030","NCT04645251","Polycystic Liver Disease Registry (UK)","PLD","Inclusion Criteria:\n\n* Patients with PLD with more than 10 liver cysts\n* Patients with PKD and PLD with more than 10 liver cysts\n\nExclusion Criteria:\n\n* Patients with PKD or PLD with less than 10 liver cysts",{"count":70,"type":20},"10 Years","Multicentre, observational registry studying the natural course of polycystic liver disease.",[220],"Polycystic Liver Disease",{"date":149,"type":30},{"date":223,"type":30},"2021-01-21",{"date":225,"type":20},"2030-12-01",{"name":35,"class":36},2,{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":235,"minAge":68,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":37},"100603395","breast-cancer-bras-study-breast-cancer-biomechanics-of-radiotherapy-and-surgery-100603395","NCT07135960","Breast Cancer BRAs Study (Breast Cancer Biomechanics of Radiotherapy And Surgery)","Breast Cancer BRAs Study (Breast Cancer Biomechanics of Radiotherapy And Surgery): The Effects of Breast Surgery and Radiotherapy on the Breast Biomechanics and Breast Support Requirements of Women Treated for Breast Cancer.","Inclusion Criteria:\n\n* Female\n* 18 years of age or above\n* Early or locally advanced breast cancer classified as B5a or B5b (radical treatment intent)\n* Unilateral breast cancer (contralateral breast used as control)\n* Receiving or has received breast cancer surgery\n* +\u002F- Adjuvant radiotherapy\n* Able to travel to the University of Portsmouth Breast biomechanics laboratory\n* Participant has capacity to consent.\n\nExclusion Criteria:\n\n* Metastatic breast cancer diagnosis\n* \\\u003C 2 weeks post-operative\n* \\\u003C 4 weeks post-radiotherapy\n* Active post-operative breast infection\n* Requirement of ongoing breast dressings\n* Previous breast surgery to contralateral breast\n* Bilateral breast cancer\n* Epilepsy (due to strobe on 3D scanner)\n* Pregnancy or \\\u003C6 weeks post-partum\n* Breastfeeding\n* Rockwood Frailty score \\>5 (or those unable to ambulate un-aided)\n* Requiring interpreter.","FEMALE",{"count":237,"type":20},45,"This study, delivered by Portsmouth Hospitals University NHS Trust in conjunction with the Research Group in Breast Health at the University of Portsmouth \\[1\\], aims to assess whether it is possible to test breast biomechanics in women who have had surgery with or without radiotherapy for the treatment of breast cancer.",[240],"Breast Cancer Patients","2025-08-20",{"date":243,"type":30},"2025-08-22",{"date":245,"type":30},"2025-02-06",{"date":247,"type":20},"2026-01-31",{"name":35,"class":36},{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":110,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":37},"100538073","a-comparison-of-diagnostic-testing-modalities-in-the-assessment-of-asthma-100538073","NCT06286085","A Comparison of Diagnostic Testing Modalities in the Assessment of Asthma","MODELS","Inclusion Criteria:\n\n* The patient will meet all the following criteria to be considered eligible for the study:\n\n  * Aged 18 years or over.\n  * All patients who have attended full asthma workups from November 2021 till date\n  * Willing and able to consent to use their data in this study (opt-out form or e-consent).\n  * Patients referred to the Portsmouth asthma service for diagnosis and further management of presumed asthma. Comorbidities are common in asthma, thus patients with co-existing conditions such as obesity, bronchiectasis or COPD will be included.\n\nExclusion Criteria:\n\n* The participant may not enter the study if either of the following apply:\n\n  * Unable to comprehend the study and provide informed consent, e.g., insufficient command of English in the absence of someone who can adequately interpret.\n  * Patients with other primary respiratory conditions, such as ILD.",{"count":257,"type":20},2000,"This study aims to assess the concordance of international asthma guidelines in the diagnosis of asthma and explore the presence of airways disease using additional non-guideline physiologic criteria, such as IOS (impulse osciollometry), not included in the guidelines, but available in the Portsmouth lung function service.",[260],"Asthma",[262,263],"lung function","impulse oscillometry","2025-07-14",{"date":266,"type":30},"2025-07-17",{"date":268,"type":30},"2024-02-27",{"date":270,"type":20},"2027-05-27",{"name":35,"class":36},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":235,"minAge":68,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":286,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":37},"100543130","feasibility-study-to-evaluate-the-use-of-patient-reported-complications-after-digital-consent-100543130","NCT06351865","Feasibility Study to Evaluate the Use of Patient Reported Complications After Digital Consent","A Feasibility Study to Evaluate if Breast Cancer Patients, Consented Using Digital Consent, Reliably Provide Accurate Patient Reported Complication (PRC) Data Using Feedback Questionnaires","PRC","Inclusion Criteria:\n\n* Consent form 1- Adult patients who have the capacity to consent for themselves.\n* Female adult aged 18years or above\n* Diagnosed with early invasive breast cancer suitable for breast conserving surgery\n* Undergoing Wide Local Excision of the breast and sentinel lymph node biopsy.\n* Participant must be able to fill out an electronic questionnaire or take part in a phone questionnaire.\n* Participant is willing and able to give informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Unable to consent for themselves or do not wish to participate.\n* Patients who need an interpreter.",{"count":281,"type":20},50,"Patient report complication data to our best knowledge has not been studied yet in electronic consent. This study is a feasibility study to assess whether patients will reliably report their complications, the quality of this reporting and whether the information provided in the consent form matches up to their experience. This data will then be used to improve the consent process and evaluate whether the Patient Initiated Follow Up (PIFU) model is effective or if it leads to underreporting of problems.",[284,285],"Breast Cancer","Complication of Surgical Procedure",{"date":266,"type":30},{"date":288,"type":30},"2024-03-07",{"date":290,"type":20},"2025-10-31",{"name":35,"class":36},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":110,"sex":17,"minAge":300,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":37},"100502260","a-trial-evaluating-novel-technologies-for-the-diagnosis-of-asthma-the-lung-tech-trial-100502260","NCT05819944","A Trial Evaluating Novel Technologies for the Diagnosis of Asthma The LUNG-TECH Trial","A Trial Evaluating Novel Technologies for the Diagnosis of Asthma","LUNG-Tech","Inclusion Criteria:\n\n* • Diagnosis confirmed by a specialist supported by any of the following within the last 5-years: i) Evidence of variable and\u002For reversible airflow obstruction\n* FEV1\u002FFVC ratio \\\u003C70% on spirometry with FEV1 ≥12% and 200 ml increase post-BD or\n* FEV1 variability ≥20% between clinic visits within 12-months or\n* R5-R20 ≥0.1kPa\u002F(L\u002Fs) with ≥40% improvement post-BD or ii) Evidence of significant peak expiratory flow (PEF) variability\n* ≥ 20% PEF variability iii) Evidence of airway hyperresponsiveness (AHR)\n* Positive methacholine challenge test (PD20 ≤8mg\u002Fml) or equivalent iv) Evidence of T2 airway inflammation\n* FeNO ≥40ppb\n\n  * Poor disease control evidenced by an ACQ-6 score ≥1.5\n  * Not on a biologic therapy for severe asthma\n\nExclusion Criteria:\n\n* • Known clinically significant chest wall, neuromuscular, cardiac or other co-morbidity or abnormality that would affect spirometry and\u002For other measures of lung function\u002Finflammation (in the opinion of the investigator)\n\n  * Respiratory tract infection\u002Fexacerbation of respiratory condition requiring systemic corticosteroids and\u002For antibiotic treatment within the last 2 weeks\n  * Current smokers or Ex-smokers with \\>20 PYH (other than COPD and asthma with significant smoking history group)\n  * The participant is unable to provide informed consent or is unable to complete the study procedures\n\nHealthy Volunteers:\n\n* No current clinical diagnosis of (or treatment for) a respiratory disease and no treatment for a respiratory tract Infection within the last 6 months\n* Never smoker or ex-smoker with ≤10 pack-years smoking history, and stopped smoking at least 6-months prior to enrolment\n* Non-obstructive spirometry","17 Years",{"count":302,"type":20},356,"This trial aims to evaluate novel diagnostic technologies for asthma in 3 different pathways providing the necessary evidence-base to allow adoption into clinical practice:\n\n* Pathway 1 evaluates whether the technology can distinguish between people with asthma and healthy volunteers, and other respiratory conditions in a well characterised secondary-care population and whether the parameters they measure correlate with the current standard diagnostic tests;\n* Pathway 2 assesses whether the technology can accurately diagnose asthma (either independently or alongside current diagnostic tests) in a primary care population of patients where there is a clinical suspicion of asthma;\n* Pathway 3 explores the ability of the technology to identify clinically important phenotypic characteristics which are difficult to measure in primary care and\u002For significantly impact on patient management and treatment\n\nThe novel technology and devices will be entered into the pathway most suited to their stage of development, with this study design also allowing information collected for participants with a confirmed diagnosis of asthma in pathways 1 or 2 to be included in pathway 3. Participants will undergo the investigations currently used to diagnose asthma as well as using the novel devices being investigated in the relevant pathway.",[260],{"date":266,"type":30},{"date":307,"type":30},"2023-01-09",{"date":309,"type":20},"2026-02-28",{"name":35,"class":36},""]